Loading...
Market
Which drug will be more effective for MASH by end of 2025: Wegovy or Rezdiffra?
2
Resolution / Starting Odds
Wegovy more effective • 25%
Rezdiffra more effective • 25%
Both equally effective • 25%
Inconclusive results • 25%
Scientific publications and clinical trial results
Story
Novo Nordisk to Seek FDA Approval for Wegovy in Treating MASH After New Data on Liver Fibrosis
Nov 1, 2024, 02:21 PM
Novo Nordisk announced plans to file for FDA approval of Wegovy to treat Metabolic Associated Steatotic Hepatitis (MASH), previously known as fatty liver disease. The decision follows the release of new data indicating the drug's potential benefits beyond weight loss. However, the data does not demonstrate improvement in liver fibrosis, a key metric where Madrigal Pharmaceuticals' Rezdiffra has shown success after its approval earlier this year. Analysts noted that while the Wegovy data is not groundbreaking, it remains significant and could warrant an update to the drug's labeling.
View original story
Similar markets
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%